Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-29 02:01 UTC

BIOMED PULSE

Tuesday, September 29, 2026 — Daily Briefing on Longevity, Viruses, and New Cures

⚡ TL;DR

The Bundibugyo virus (Ebola) outbreak in the Democratic Republic of the Congo has now reached 61 health zones across six provinces and a seventh province (Sud Ubangi), making it the largest Ebola outbreak ever recorded in the DRC — the situation is dire and worsening. Alongside active food-safety alerts and promising longevity biomaterial research, today's overall mood is urgent on outbreak containment and cautiously optimistic on aging science.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS (EBOLA) — DRC AND UGANDA: LARGEST EBOLA OUTBREAK ON RECORD

  • As of September 25, 2026, the Bundibugyo virus disease (BVD) outbreak in the DRC has expanded to two additional health zones, including Bulu in the newly affected province of Sud Ubangi in the country's northwest. [1]
  • The outbreak now spans 61 health zones across six confirmed provinces: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo, plus the new seventh province. [2] [1]
  • As of the August 28 DON, the outbreak had already spread from 54 to 60 health zones, with cross-border transmission to Uganda persisting throughout. [3]
  • WHO classified this as the largest Ebola outbreak ever reported in the DRC, expanding faster than any previous outbreak in the country's history. [4]
  • For context: confirmed cases reached 2,124 with 828 deaths as of July 15, 2026; the case fatality ratio among confirmed cases remains extremely high. [5]
  • The outbreak originated in Mongbwalu Health Zone, Ituri Province, after an alert on May 5, 2026 of a high-mortality illness of unknown cause that was killing health workers. [6]
  • Bundibugyo virus was confirmed by the Institut national de recherche biomédicale (INRB) on May 14, 2026; DRC and Uganda jointly declared the outbreak on May 15, 2026. [6] [7]

LISTERIA — PREPARED MEALS OUTBREAK UPDATE

  • CDC expanded a Listeria monocytogenes outbreak linked to additional prepared foods on September 26, 2026, reporting 3 new illnesses and 1 additional death in this latest update. [8] [9]
  • CDC continues to urge consumers to check refrigerators and freezers for recalled prepared meal products and discard them immediately, as new illnesses were still being reported despite prior recalls. [10]

DRUG-RESISTANT BACTERIA: SHARP RISE REPORTED

  • A CDC report published September 23, 2026 found a dramatic increase in dangerous drug-resistant bacteria, signaling a worsening antimicrobial resistance trend in the United States.

CONGENITAL SYPHILIS: 12TH CONSECUTIVE YEAR OF INCREASE

  • New CDC data released September 24, 2026 shows U.S. cases of syphilis in newborns increased for the 12th consecutive year in 2024.

ANIMAL RABIES ACTIVITY RISING

  • CDC issued a statement on September 10, 2026 warning of increases in recent animal rabies activity and associated human exposure events nationwide.

LUNG CANCER DRIVING DOWN CANCER MORTALITY

  • The Annual Report to the Nation published September 22, 2026 shows progress against lung cancer is a primary driver of declining overall U.S. cancer death rates.

🧬 LONGEVITY & AGING

YOUNG PLASMA EXOSOMES AND ALZHEIMER'S DISEASE

  • Researchers (Chen H et al., Bioactive Materials, August 2026) investigated engineered exosomes derived from young plasma as a potential therapeutic strategy for Alzheimer's disease, exploring the underlying mechanisms by which youthful extracellular vesicles might slow neurodegeneration.

SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP) CHARACTERIZATION IN SKIN CELLS

  • Koutsoukos SA et al. (Methods in Molecular Biology) developed multiplex assay methods to characterize the SASP in both primary and induced pluripotent stem cell-derived skin cells, providing new tools to study how senescent cells drive inflammation and aging-related tissue decline.

IONIZING RADIATION DRIVES CELLULAR SENESCENCE VIA FOXM1-KIF20A PATHWAY

  • Jia Z et al. (Genes and Disease, March 2026) found that ionizing radiation induces senescence in dermal papilla cells specifically by inhibiting the FOXM1-KIF20A signaling pathway, linking radiation exposure to accelerated cellular aging in hair follicle tissue.

MRNA LIPID NANOPARTICLE TARGETS AGE-RELATED BONE DEFECTS

  • Cheng M et al. (Bioactive Materials, August 2026) engineered a dual-targeting mRNA lipid nanoparticle that restores ABCA1-dependent cholesterol homeostasis in aged bone, promoting repair of age-related skeletal defects — a mechanism-driven approach to reversing bone aging at the cellular level.

SINGLE-CELL TRANSCRIPTOMICS GUIDES AGED BONE REGENERATION HYDROGEL

  • Gu HY et al. (Biomaterials, August 2026) used single-cell transcriptomic data to design a cascade-responsive hydrogel incorporating a bioinspired nanocellular pacemaker specifically optimized for regenerating bone in aged biological microenvironments.

MOLECULAR HYDROGEN AS RADIOPROTECTION AGENT

  • Ichikawa Y et al. (Medical Gas Research, September 2026) reviewed evidence that molecular hydrogen may act as a guardian against environmental radiation-induced biological damage, potentially relevant to both radiation therapy side effects and aging-related oxidative stress.

QUERCETIN-DERIVED NANOCOMPOSITE FOR OSTEOPOROTIC BONE REPAIR

  • Yin H et al. (Bioactive Materials, August 2026) developed a quercetin-derived carbon dot and ZIF-8 nanocomposite hydrogel functionalized with M2 macrophage-derived migrasomes, designed to regenerate osteoporotic bone defects in the aged microenvironment.

EXTRACELLULAR VESICLES IN OSTEOARTHRITIS: CONTEXT-DEPENDENT ROLES

  • Yang Z et al. (Bioactive Materials, September 2026) reviewed how extracellular vesicles can shift from pathogenic drivers to reparative agents in osteoarthritis, a disease of aging joints, depending on microenvironmental context — with implications for cell-free therapeutic design.

💊 NEW CURES & APPROVALS

VERZENIO (ABEMACICLIB) — ELI LILLY AND CO: SUPPLEMENTAL APPROVAL

  • Eli Lilly and Co received a supplemental FDA approval (SUPPL AP) for VERZENIO (abemaciclib), a CDK4/6 inhibitor used in hormone receptor-positive, HER2-negative breast cancer — a disease disproportionately affecting women in midlife and beyond.

INLURIYO (IMLUNESTRANT TOSYLATE) — ELI LILLY AND CO: SUPPLEMENTAL APPROVAL

  • Eli Lilly and Co received a supplemental FDA approval for INLURIYO (imlunestrant tosylate), an oral selective estrogen receptor degrader (SERD) targeting ER-positive breast cancer.

WINREVAIR (SOTATERCEPT-CSRK) — MERCK SHARP AND DOHME: SUPPLEMENTAL APPROVAL

  • Merck Sharp and Dohme received a supplemental FDA approval for WINREVAIR (sotatercept-csrk), an activin signaling inhibitor indicated for pulmonary arterial hypertension — a disease with high mortality in older adults.

SOHONOS (PALOVAROTENE) — IPSEN: SUPPLEMENTAL APPROVAL

  • Ipsen received a supplemental FDA approval for SOHONOS (palovarotene), a retinoic acid receptor gamma agonist used in fibrodysplasia ossificans progressiva (FOP), a severe rare disease causing progressive bone formation in soft tissues.

SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — NOVARTIS: SUPPLEMENTAL APPROVAL

  • Novartis received a supplemental FDA approval for SCEMBLIX (asciminib hydrochloride), a STAMP inhibitor targeting BCR-ABL1 for chronic myeloid leukemia (CML), for an updated or expanded indication.

NUBEQA (DAROLUTAMIDE) — BAYER HEALTHCARE: SUPPLEMENTAL APPROVAL

  • Bayer Healthcare received a supplemental FDA approval for NUBEQA (darolutamide), an androgen receptor inhibitor used in prostate cancer, for an expanded indication.

AQNEURSA (LEVACETYLLEUCINE) — INTRABIO: SUPPLEMENTAL APPROVAL

  • IntraBio received a supplemental FDA approval for AQNEURSA (levacetylleucine), indicated for neurological manifestations of Niemann-Pick disease type C, a lysosomal storage disorder with progressive neurodegeneration.

DEFLAZACORT — HIKMA: ORIGINAL APPROVAL (GENERIC)

  • Hikma received an original ANDA approval for deflazacort, a corticosteroid used in Duchenne muscular dystrophy, expanding generic access to this treatment.

LANREOTIDE ACETATE — AMNEAL: ORIGINAL APPROVAL (GENERIC)

  • Amneal received an original ANDA approval for lanreotide acetate, a somatostatin analogue used in acromegaly and neuroendocrine tumors, expanding the generic market for this injectable therapy.

🧪 CLINICAL TRIALS

PIRTOBRUTINIB FOR ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  • A Phase II trial (NCT07685717) is studying pirtobrutinib, a noncovalent BTK inhibitor, in elderly patients with chronic lymphocytic leukemia (CLL) — specifically addressing the underserved older patient population where BTK inhibitor tolerability is a key concern.

EXPEC9V VACCINE IN ADULTS AGED 60 AND OLDER FOR URINARY TRACT INFECTION PREVENTION

  • Trial NCT04899336 is evaluating the efficacy of a 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) vs. placebo in adults aged 60 and older with a history of UTI in the past 2 years, targeting a major driver of hospitalization in the elderly.

IL-12 GENETICALLY ENGINEERED MYELOID CELLS IN SOLID TUMORS

  • Trial NCT07672483 is testing IL-12-producing genetically engineered myeloid cells (IL-12 GEMys) in participants with relapsed or refractory solid tumors, exploring whether engineered innate immune cells can activate tumor-killing responses.

COMBINATION MIRDAMETINIB AND SIROLIMUS FOR RAS-MUTATED RELAPSED REFRACTORY MYELOMA

  • Trial NCT06876142 is studying the combination of mirdametinib (MEK inhibitor) and sirolimus (mTOR inhibitor) in patients with KRAS/NRAS-mutated relapsed refractory multiple myeloma, targeting a currently undruggable resistance mechanism.

COVID-19 VACCINE SAFETY AND EFFICACY STUDY IN AGES 5 TO 65-PLUS

  • Trial NCT07798648 is evaluating updated BNT162b2 COVID-19 vaccines in participants aged 5 through 64 with risk factors for severe disease, and in all adults aged 65 and older, with a focus on safety, immunogenicity, and protection in older and higher-risk populations.

(2R,6R)-HNK AS A NON-ADDICTIVE ANALGESIC IN HEALTHY VOLUNTEERS

  • Trial NCT07504601 is investigating (2R,6R)-hydroxynorketamine, a ketamine metabolite, for acute pain in healthy volunteers, aiming to find non-opioid pain relief without addiction risk — relevant to chronic pain management in aging populations.

📢 PUBLIC HEALTH

LISTERIA AND SALMONELLA FOOD SAFETY: MULTIPLE ACTIVE ALERTS

  • CDC warns that Listeria illnesses linked to prepared meals continued despite recalls as of October 30, 2025 (ongoing into 2026), urging consumers to check for recalled products at home. [10]
  • A Salmonella outbreak linked to Metabolic Meals home delivery foods had sickened 16 people in 10 states as of September 5, 2025, with the investigation ongoing.
  • A Salmonella outbreak linked to recalled eggs had sickened 95 people across 14 states as of August 28, 2025 — one of the largest recent egg-linked outbreaks.

CDC IMMUNIZATION SCHEDULE UPDATED: INDIVIDUAL-BASED COVID-19 AND STANDALONE CHICKENPOX DECISIONS

  • CDC updated its adult and child immunization schedules (effective October 6, 2025) to apply individual-based clinical decision-making for COVID-19 vaccines and to allow standalone varicella (chickenpox) vaccination for toddlers.

DRUG OVERDOSE DEATHS DOWN 27 PERCENT

  • CDC provisional 2024 data show a 27% decrease in U.S. drug overdose deaths, building on the nearly 24% decline reported for 2023 — the most sustained drop on record.

U.S. HAS COMPLETED WITHDRAWAL FROM WHO

  • The United States completed its formal withdrawal from the World Health Organization on January 22, 2026, citing COVID-19 management failures and organizational politicization, shifting to bilateral health partnerships.
  • WHO stated that the U.S. withdrawal makes both the United States and the world less safe, noting issues to be addressed by the WHO Executive Board and World Health Assembly.

YOUTH HEALTH PROGRESS: POSITIVE DATA

  • CDC data released September 21, 2026 show encouraging progress across multiple youth health metrics, including continued declines in tobacco and e-cigarette use.

This briefing is informational only and does not constitute medical advice. Always consult a qualified healthcare professional for medical decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  6. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  7. Ebola disease caused by Bundibugyo virus – Democratic Republic… — WHO Disease Outbreak News
  8. CDC expands Listeria outbreak to include more prepared meals — CDC Newsroom
  9. Listeria Outbreak to include more Prepared Foods — CDC Newsroom
  10. CDC continues to note illnesses despite product recalls and as… — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260929-02-v90 · 2026-09-29 02:01 UTC · pulse.uzylab.com

Read next